

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Advanced Enzyme Technologies Limited

Report on the Audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying Consolidated Annual Financial Results of **Advanced Enzyme Technologies Limited** (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2026, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries the aforesaid Statement:

(i) includes the annual financial results of the Holding Company and the following entities

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly owned subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of AEU
5	Cal India Foods International ('CAL')	Wholly owned subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly owned subsidiary of CAL
7	Starya Labs, Inc.	Wholly owned subsidiary of AEU
8	JC Biotech Private Limited	Subsidiary
9	Scitech Specialities Private Limited	Subsidiary
10	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly owned subsidiary
11	Evoxx Technologies GmbH	Wholly owned subsidiary of AEEBV
12	Saiganesh Enzytech Solutions Private Limited	Subsidiary
13	Advanced Nutrazyme Private Limited ('ANPL')	Wholly Owned Subsidiary (with effect from July 04, 2025)

MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the consolidated net Profit and consolidated other comprehensive income and other financial information of the Group, for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated annual financial results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Annual Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

This Statement has been prepared on the basis of the Consolidated Annual financial statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. The respective Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are responsible for overseeing the financial reporting process of each Company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated annual financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial results of such entity included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

MSKA & Associates LLP

(Formerly known as M S K A & Associates)
Chartered Accountants

We communicate with those charged with governance of the Holding Company included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters:

The Statement includes the audited financial statements of thirteen subsidiaries whose financial statements reflect total assets of Rs. 12,717.38 million as at March 31, 2026, total revenue of Rs. 4,722.85 million, net profit after tax of Rs. 984.67 million, total comprehensive income of Rs. 1,950.35 million and net cash inflow of Rs. 182.40 million for the year ended on that date, as considered in the Statement, which have been audited by the other auditors. The Other auditor's report on the financial statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W

Amrish Vaidya
Anup Vaidya
Date: 2026.05.09
12:42:40 +05'30'

Amrish Vaidya

Partner

Membership No.: 101739

UDIN: 26101739ZVWLQR8755

Place: Mumbai

Date: May 09, 2026

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220, Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id: sanjay@advancedenzymes.com

Statement of audited consolidated financial results for the quarter and year ended 31 March 2026

(₹ in million except per share data)

Particulars	Quarter ended			Year ended	
	31-Mar-26 Audited (refer note vi)	31-Dec-25 Unaudited	31-Mar-25 Audited (refer note vi)	31-Mar-26 Audited	31-Mar-25 Audited
1 Revenue from operations	2,033.67	1,719.49	1,671.79	7,457.57	6,369.10
2 Other Income	72.28	84.69	87.45	348.32	330.41
3 Total Income (1+2)	2,105.95	1,804.18	1,759.24	7,805.89	6,699.51
4 Expenses					
(a) Cost of materials consumed	559.61	456.40	459.42	1,943.12	1,619.56
(b) Purchases of stock-in-trade #	0.00	0.00	-	0.00	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	9.69	(42.34)	1.45	(13.61)	(100.95)
(d) Employee benefits expense (refer note iv)	419.38	412.62	368.37	1,622.86	1,415.42
(e) Finance costs (including exchange difference)	5.73	5.68	8.11	26.28	35.57
(f) Depreciation and amortisation expense	101.92	102.06	100.76	400.93	365.56
(g) Other expenses	412.71	399.31	386.53	1,614.54	1,490.71
Total Expenses	1,509.04	1,333.73	1,324.64	5,594.12	4,825.87
5 Profit before exceptional item and tax (3-4)	596.91	470.45	434.60	2,211.77	1,873.64
6 Exceptional item (charge / (credit)) (refer note ix & x)	(1.13)	(112.46)	-	(113.59)	-
7 Profit before tax (5-6)	598.04	582.91	434.60	2,325.36	1,873.64
8 Tax expense					
Current tax	133.48	119.36	141.48	564.46	495.33
Deferred tax charge / (credit)	12.04	31.72	25.84	24.82	38.57
Total tax expense	145.52	151.08	167.32	589.28	533.90
9 Net profit for the period (7-8)	452.52	431.83	267.28	1,736.08	1,339.74
10 Other comprehensive income					
A (i) Items that will not be reclassified to profit or loss					
Remeasurements of defined benefit liability/(asset)	6.05	6.97	(3.92)	13.40	(6.78)
(ii) Income tax related to items that will not be reclassified to profit or loss	(1.50)	(1.76)	0.97	(3.37)	1.77
B (i) Items that will be reclassified to profit or loss					
Exchange differences in translating financial statements of foreign operations	474.78	113.80	9.54	938.08	193.23
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive income	479.33	119.01	6.59	948.11	188.22
11 Total comprehensive income (9+10)	931.85	550.84	273.87	2,684.19	1,527.96
12 Net profit attributable to:					
Shareholders of the Company	429.63	425.00	264.82	1,687.19	1,311.15
Non-controlling interest	22.89	6.83	2.46	48.89	28.59
13 Other comprehensive income attributable to:					
Shareholders of the Company	479.16	118.50	6.55	947.42	188.26
Non-controlling interest	0.17	0.51	0.04	0.69	(0.04)
14 Total comprehensive income attributable to:					
Shareholders of the Company	908.79	543.50	271.37	2,634.61	1,499.41
Non-controlling interest	23.06	7.34	2.50	49.58	28.55
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.85	223.85	223.76	223.85	223.76
16 Other equity				16,095.72	13,984.87
17 Earnings Per Share of ₹ 2 each (not annualized)					
(a) ₹ (Basic)	3.84	3.80	2.37	15.08	11.72
(b) ₹ (Diluted)	3.84	3.79	2.37	15.06	11.71

Figures are below Rs. 0.01 Million, hence disclosed as Rs. 0.00

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of consolidated assets and liabilities

(₹ in million)

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
I. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment	2,758.32	2,929.41
(b) Capital work-in-progress	511.69	216.91
(c) Goodwill	3,694.60	3,334.40
(d) Other Intangible assets	469.22	522.91
(e) Intangible assets under development	-	0.17
(f) Financial Assets		
(i) Investments	0.64	0.65
(ii) Loans	0.96	0.65
(ii) Other financial assets	96.84	99.19
(g) Deferred tax assets (net)	48.78	101.92
(h) Income tax assets (net)	230.33	177.69
(i) Other non-current assets	140.49	30.88
Total non-current assets	7,951.87	7,414.78
(2) Current Assets		
(a) Inventories	1,772.77	1,573.05
(b) Financial Assets		
(i) Investments	5,838.30	4,802.58
(ii) Trade receivables	1,450.20	1,153.99
(iii) Cash and cash equivalents	1,087.55	942.25
(iv) Bank balances other than (iii) above	71.76	134.60
(v) Loans	2.43	1.03
(vi) Other financial assets	86.25	80.48
(c) Other current assets	126.48	110.71
Total current assets	10,435.74	8,798.69
Total assets	18,387.61	16,213.47
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	223.85	223.76
(b) Other equity	16,095.72	13,984.87
Equity attributable to the owners of the Company	16,319.57	14,208.63
Non-controlling interest	511.65	478.07
Total equity	16,831.22	14,686.70
(3) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	78.87	91.83
(ii) Lease liability	37.69	117.34
(b) Provisions	53.88	18.79
(c) Deferred tax liabilities (net)	318.73	336.34
Total non-current liabilities	489.17	564.30
(4) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	126.41	123.53
(ii) Lease liability	77.12	60.80
(iii) Trade payables		
a) total outstanding dues of micro enterprises and small enterprises	63.91	42.93
b) total outstanding dues of creditors other than micro enterprises and small enterprises	335.68	151.89
(iv) Other financial Liabilities	285.08	243.52
(b) Other current liabilities	104.94	85.28
(c) Provisions	63.94	208.60
(d) Current tax liabilities (net)	10.14	45.92
Total current liabilities	1,067.22	962.47
Total equity and liabilities	18,387.61	16,213.47

STATEMENT OF CONSOLIDATED CASHFLOW

(₹ in million)

		Year ended 31 March 2026 Audited	Year ended 31 March 2025 Audited
A.	Cash flows from operating activities		
	Profit before tax	2325.36	1873.64
		2325.36	1873.64
	Adjustments for non-cash transactions		
	Depreciation and amortization expense	400.93	365.56
	Prepaid lease amortisation	0.18	0.18
	Property, plant and equipments written off	3.63	-
	(Profit)/Loss on sale of Property, plant and equipments	1.04	(2.17)
	Allowances for bad and doubtful trade receivables	(9.11)	9.25
	Bad and doubtful trade receivables written off	3.64	6.43
	Provision for doubtful trade receivables written back	-	(0.38)
	Employee stock compensation expense	48.60	34.46
	Excess provision written back	(161.35)	(1.98)
	Sundry balances written (back)/ off (net)	0.02	(0.01)
	Fair valuation of investments in marketable securities	(96.57)	(82.25)
	Provision for inventory	12.77	2.08
	Provision for investments	-	1.01
	Unrealized foreign exchange (gain)	(4.26)	(0.84)
		2,524.88	2,204.98
	Items considered separately		
Interest income	(186.64)	(96.72)	
Interest expenses	26.28	35.75	
Operating profit before working capital changes	2,364.52	2,144.01	
Adjustments for:			
(Increase) / Decrease in non-current loans	(0.96)	(0.44)	
(Increase) / Decrease in other non-current financial assets	(1.28)	(1.27)	
(Increase) / Decrease in other non-current assets	5.98	3.02	
(Increase) / Decrease in inventories	(162.47)	(77.97)	
(Increase) / Decrease in trade receivables	(258.64)	(177.29)	
(Increase) / Decrease in Current loans	(1.40)	(0.02)	
(Increase) / Decrease in financial current assets	(5.58)	113.73	
(Increase) / Decrease in Other current assets	(13.68)	18.20	
(Decrease) / Increase in provisions	58.47	10.48	
(Decrease) / Increase in trade payables	194.72	34.87	
(Decrease) / Increase in current financial liabilities - others	27.17	(13.15)	
(Decrease) / Increase in other current liabilities	12.18	(32.46)	
Cash generated from operating activities	2219.03	2021.71	
Income taxes paid (net of refund)	(651.27)	(596.74)	
Net cash generated from operating activities	1,567.76	1,424.97	
B.	Cash flows from investing activities		
	Purchase of property, plant and equipment	(522.30)	(338.08)
	Proceeds from sale of property, plant and equipments	4.47	5.27
	Purchase of intangible assets	(1.47)	(9.73)
	(Purchase) / Proceeds from sale of current investments (net)	(472.54)	(590.42)
	Interest received	182.09	99.43
	(Increase) in bank deposits with maturity more than 3 months but less than 12 months	(12.08)	(1.94)
	(Increase) / Decrease in bank deposits with maturity of more than 12 months	80.53	(55.54)
Net cash (used in) investing activities	(741.30)	(891.01)	
C.	Cash flows from financing activities		
	Proceeds from issue of share capital including securities premium	9.53	3.78
	(Repayment)/proceeds from long-term borrowings (net)	(12.86)	22.30
	(Repayment)/proceeds from short-term borrowings (net)	2.78	(58.08)
	Interest paid	(24.21)	(33.42)
	Lease liability paid	(81.12)	(69.72)
	Dividends paid	(597.78)	(590.30)
	Net cash (used in) financing activities	(703.66)	(725.44)
	Net (decrease) / increase in cash and cash equivalents (A+B+C)	122.80	(191.48)
	Cash and cash equivalents as at the beginning of the year	942.25	1137.51
Effect of exchange rate changes on cash and cash equivalents held	22.50	(3.78)	
Cash and cash equivalents as at the end of the period	1,087.55	942.25	
Composition of cash and cash equivalents	Cash in hand (including cheques on hand)	3.20	0.96
	Balance with banks :		
	Current account	494.43	266.14
	Fixed deposit account (with maturity less than 3 months)	24.07	7.65
	Liquid fund balance (with maturity less than 3 months)	565.85	667.50
	1,087.55	942.25	

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above audited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Nutrazyme Private Limited (India)(w.e.f. 4 July 2025), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Starya Labs, Inc. (U.S.A.)(w.e.f. 09 December 2024), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above audited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 9 May 2026. The above results have been audited by the statutory auditors of the Company and they have expressed an unmodified opinion. The audit report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iv) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(v) The Group has allotted 45,650 equity shares during the year ended 31 March 2026 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(vi) The figures for the quarter ended 31 March 2026 and the corresponding quarter ended in previous year as reported in these consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(vii) The Board of Directors in its meeting held on 9 May 2026 have proposed the final dividend for the financial year 2025-26 of Rs. 1.35/- per equity share and the same will be paid after approval by the shareholders of the Company in its Annual General Meeting.

(viii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(ix) On November 21, 2025, the Government of India notified the four Labour Codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 – consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations.

The Group has assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. The current assessment is based on the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" in the consolidated financial results.

The impact for the quarter ended 31 December 2025 consisting of gratuity of Rs. 45.67 million and compensated absences of Rs. 1.51 million was accounted in the consolidated financial results primarily due to change in wage definition. Further, for the quarter ended 31 March 2026, additional impact of gratuity of Rs. 0.63 million has been recognised. The impact for the year ended 31 March 2026 pertaining to gratuity is Rs. 46.30 million and compensated absences is Rs. 1.51 million

The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would accordingly take necessary steps for compliance thereof and also provide appropriate accounting effect on the basis of such developments, as needed.

(x) On 22 August 2025, United States court of appeals have directed the District of Arizona to pass the order in favour of Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzyme USA, Inc. (U.S.A.) for the lawsuit filed by the Competitor. Based on the above direction of United States Court of Appeals and legal opinion received in the quarter ended 31 December 2025, the provision created amounting to Rs. 159.64 million earlier with respect to the mentioned lawsuit was reversed. Further, for the quarter ended 31 March 2026, additional impact of Rs. 1.75 million has been recognised on account of foreign exchange fluctuation. The cumulative impact for the year ended 31 March 2026 pertaining to the above mentioned lawsuit is Rs. 161.39 million

By Order of the Board of Directors

For Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

MUKUND Digitally signed
by MUKUND
MADHUS
UDAN MADHUSUDAN
KABRA
Date: 2026.05.09
12:34:58 +05'30'

M.M. Kabra

Wholetime Director

DIN : 00148294

Place: California, United States of America

Dated: 9 May 2026